Welcome to our dedicated page for Proassurance Cp SEC filings (Ticker: PRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the financial health of a specialty insurer like ProAssurance can feel daunting鈥攖he latest 10-K spans multiple liability segments, reinsurance treaties, and reserve calculations. Investors trying to pinpoint healthcare liability loss ratios or monitor ProAssurance insider trading Form 4 transactions often spend hours scrolling through dense language.
Stock Titan solves this with real-time EDGAR feeds and AI-powered summaries. The moment a filing hits EDGAR鈥�ProAssurance 8-K material events explained instantly鈥攜ou鈥檒l see a concise plain-English note. Our platform highlights section references inside every ProAssurance annual report 10-K simplified, flags shifts in combined ratios inside each ProAssurance quarterly earnings report 10-Q filing, and streams ProAssurance Form 4 insider transactions real-time so you can act before the market reacts.
Need quick answers? Type natural questions like 鈥�understanding ProAssurance SEC documents with AI鈥� or 鈥�ProAssurance proxy statement executive compensation鈥� and jump straight to our plain-English notes. Use cases include:
- Comparing reserve development with our ProAssurance earnings report filing analysis
- Monitoring ProAssurance executive stock transactions Form 4 ahead of dividend announcements
- Reviewing claim severity trends via ProAssurance SEC filings explained simply
Whether you鈥檙e an equity analyst tracking the Lloyd鈥檚 syndicate result or a healthcare CFO verifying coverage ratios, Stock Titan delivers every filing type鈥�10-K, 10-Q, 8-K, S-1, DEF 14A鈥攃omplete with AI context. Skip the jargon, keep the insight.
Tempus AI, Inc. (symbol TEM) filed a Form 144 indicating that insider Ryan Fukushima intends to sell 20,000 common shares through Morgan Stanley Smith Barney on or about 07/07/2025. At the reference price used in the filing, the shares have an aggregate market value of $1.22 million. The proposed sale represents roughly 0.012 % of the company鈥檚 168.1 million shares outstanding.
The stock was originally acquired as restricted-stock awards on 10/14/2015. The form also discloses that, within the past three months, the same insider (including 10b5-1 plan sales) has already disposed of 47,820 shares, generating gross proceeds of approximately $2.79 million across three transactions (20 k on 06/03/2025, 7.82 k on 05/20/2025, and 20 k on 05/06/2025).
The filing does not disclose any material non-public information and states the seller鈥檚 representation of compliance with Rule 10b5-1. While the dollar value is meaningful, the percentage of ownership being liquidated is small, suggesting limited direct impact on the share float. Nevertheless, continued insider selling can influence investor sentiment.
ProAssurance Corporation (NYSE: PRA) reported that shareholders overwhelmingly approved all proposals connected with its pending merger with The Doctors Company at a special meeting held on 24 June 2025.
鈥� Merger Agreement adoption: 38,225,337 shares voted FOR, just 363,050 AGAINST and 22,192 ABSTAIN; no broker non-votes were recorded. Support exceeded 99% of votes cast, comfortably surpassing any approval threshold.
鈥� Say-on-Pay (merger-related compensation): 31,191,544 FOR, 7,185,578 AGAINST, 233,457 ABSTAIN鈥攁n 81% approval rate on an advisory basis.
鈥� Adjournment proposal: Not required because quorum (鈮�75.6% of outstanding 51,070,243 shares) was achieved and the merger proposal passed.
Under the Agreement and Plan of Merger signed 19 March 2025, Jackson Acquisition Corporation (a wholly owned subsidiary of The Doctors Company) will merge with and into ProAssurance, making ProAssurance a wholly owned subsidiary of The Doctors Company. Management currently expects closing in the first half of 2026, subject to regulatory clearances and other customary conditions.
The filing reiterates extensive forward-looking risk factors, including regulatory approvals, potential litigation, business disruption, personnel retention and market reactions during the pre-closing period. A related news release (Exhibit 99.1) announcing the vote results was issued the same day.
FAQ
What is the current stock price of Proassurance Cp (PRA)?
What is the market cap of Proassurance Cp (PRA)?
What is the core business of ProAssurance Cp?
What types of insurance products does ProAssurance offer?
How does ProAssurance generate its revenue?
Which segments constitute ProAssurance's operations?
How does ProAssurance differentiate itself in the market?
Who are the primary customers of ProAssurance?
What role does risk management play at ProAssurance?
How does ProAssurance address the evolving needs of healthcare liability?
